Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in newly diagnosed type 1 diabetes
NCT07222332Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2026
- Primary completion
- Jul 2028
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 20
01
Overview
A Phase 3 trial of baricitinib in type 1 diabetes mellitus (T1D), sponsored by Eli Lilly and Company. Started Feb 2026; status: recruiting.
02
Drugs
baricitinib
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07222332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07222332.